Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication LYRICA is indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: • Neuropathic pain associated with diabetic…
pregabalin · 1 trial · 2 indications
Numerical Pain Rating Scale (NPRS) will be assessed during Cold Pressor Tests at various time points for time to reach Pain Detection Threshold (PDT) and time to reach Pain Tolerance Threshold (PTT)
Stopwatches will be used during each cold pressor test to determine time for subject to reach PDT and PTT
| Arm | Type | Description |
|---|---|---|
| Schedule A | OTHER | participants receive pregabalin 300mg in treatment period 1, and receive placebo in treatment period 2 |
| Schedule B | OTHER | participants receive placebo in treatment period 1, and receive pregabalin 300mg in treatment period 2 |
| Name | Type | Description |
|---|---|---|
| pregabalin 300 mg | DRUG | pregabalin is an FDA-approved anticonvulsant medication commonly used to treat nerve pain |
| Placebo | OTHER | biologically inactive placebo comparator |
Inclusion Criteria: 1. Male participants aged 18 to 55 years, inclusive, at the time of signing the informed consent. 2. Overtly healthy with no clinically relevant abnormalities based on the medical history, physical examinations, clinical laboratory evaluations, and 12-lead ECG that, in the opini...